CORRELATION BETWEEN aPTT AND ANTIFACTOR Xa TO DETERMINE THERAPEUTIC RANGES FOR UNFRACTIONATED HEPARIN

Correlación de Valores de TTPa con Anti Factor Xa para establecer rango terapéutico en tratamiento anticoagulante con Heparina Sódica.

Author
Mariné, Leopoldo; (1) Departamento de Cirugía Vascular y Endovascular, Pontificia Universidad Católica de Chile. Santiago, Chile.

Sánchez, Gonzalo; (1) Departamento de Cirugía Vascular y Endovascular, Pontificia Universidad Católica de Chile. Santiago, Chile.

Vargas, José Francisco; Departamento de Cirugía Vascular y Endovascular, Pontificia Universidad Católica de Chile. Santiago, Chile.

Zúñiga, Pamela; (2) Departamento de Hematología, Pontificia Universidad Católica de Chile. Santiago, Chile.

Aizman, Andrés; (3) Departamento de Medicina Interna, Pontificia Universidad Católica de Chile. Santiago, Chile.

Mertens, Renato; Departamento de Cirugía Vascular y Endovascular, Pontificia Universidad Católica de Chile. Santiago, Chile.

Bergoeing, Michel; Departamento de Cirugía Vascular y Endovascular, Pontificia Universidad Católica de Chile. Santiago, Chile.

Muñoz, Blanca; (4) Laboratorio de Hemostasia, Pontificia Universidad Católica de Chile. Santiago, Chile.

Full text
http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/3471
Abstract
Background: The therapeutic range (TR) of activated partial thromboplastin time (aPTT) for unfractionated heparin (UFH) dosing was established in the 1970 decade. Since then aPTT determination has changed. Current TR may be sub or supra-therapeutic depending on the reagents of the test, and therefore, responsible for complications of therapy. Aim: To establish the TR for UFH dosing in our institution using antifactor Xa analysis as reference standard. Material and methods: After obtaining an informed consent, 43 blood samples were obtained for aPTT determination and antifactor Xa assay in 23 patients treated with intravenous UFH. Samples were processed at Emergency and Hemostasis Labs. We excluded patients receiving other anticoagulants, with thrombophilia, pregnancy or liver disease. Results: Mean aPTT values in the Hemostasis and Emergency labs were 57.1±18.9 and 56.6±18.3 seconds, respectively (p=0.77). The squared correlation coefficients between aPTT and antifactor Xa at hemostasis and emergency labs were R2 0.5 and 0.45 respectively, p
 
Background: The therapeutic range (TR) of activated partial thromboplastin time (aPTT) for unfractionated heparin (UFH) dosing was established in the 1970 decade. Since then aPTT determination has changed. Current TR may be sub or supra-therapeutic depending on the reagents of the test, and therefore, responsible for complications of therapy. Aim: To establish the TR for UFH dosing in our institution using antifactor Xa analysis as reference standard. Material and methods: After obtaining an informed consent, 43 blood samples were obtained for aPTT determination and antifactor Xa assay in 23 patients treated with intravenous UFH. Samples were processed at Emergency and Hemostasis Labs. We excluded patients receiving other anticoagulants, with thrombophilia, pregnancy or liver disease. Results: Mean aPTT values in the Hemostasis and Emergency labs were 57.1±18.9 and 56.6±18.3 seconds, respectively (p=0.77). The squared correlation coefficients between aPTT and antifactor Xa at hemostasis and emergency labs were R2 0.5 and 0.45 respectively, p
 
Metadata
Show full item record